Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | IDH1 | O75874 | 12/20 | 0.48 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20565860 | 0.86 | HDAC3 (0.70) | HDAC3HDAC1HDAC10HDAC6NPC1 | |
| SCHEMBL4917592 | 0.85 | HDAC3 (0.56) | HDAC3HDAC1HDAC10HDAC6NPC1 | |
| SCHEMBL4920409 | 0.83 | OPRM1 (0.45) | HDAC3HDAC1HDAC10HDAC6TP53 | |
| SCHEMBL4910158 | 0.81 | CYP1A2 (0.50) | NPC1TP53RAB9ASMN1; SMN2OGFRL1 | |
| SCHEMBL4916973 | 0.79 | OPRM1 (0.57) | HDAC3HDAC1HDAC10HDAC6TP53 | |
| SCHEMBL4918061 | 0.79 | NR4A2 (0.46) | RAB9ASMN1; SMN2OGFRL1 | |
| SCHEMBL4918658 | 0.78 | NR4A2 (0.45) | HDAC3HDAC1HDAC10HDAC6TP53 | |
| SCHEMBL6161817 | 0.76 | CYP11B2 (0.60) | HDAC1HDAC6OGFRL1 | |
| SCHEMBL9876669 | 0.76 | TP53 (0.46) | TP53OGFRL1 | |
| SCHEMBL9685823 | 0.76 | RPS6KB1 (0.47) | TP53OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058376-A1 | PIPERIDINES | ICAGEN, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7244744-B2 | Piperidines | ICAGEN, INC. (US) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058376-A1 | PIPERIDINES | TRPV3, SCN3A, TRPV1 | HDAC3 608/4885HDAC1 2146/4885HDAC10 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.